Rapt therapeutics, inc. (RAPT)
Income statement / Quarterly
Mar'20Sep'19Mar'19Sep'18
Revenue

935

-

-

-

Operating expenses:
Research and development

10,683

8,582

7,870

9,181

General and administrative

3,289

1,733

1,674

1,364

Total operating expenses

13,972

10,315

9,544

10,545

Loss from operations

-13,037

-10,315

-9,544

-10,545

Other income
Other income, net

135

344

356

261

Net loss before taxes

-12,902

-

-9,188

-

Provision for income taxes

237

-

0

-

Net loss

-13,139

-9,971

-9,188

-10,284

Other comprehensive loss:
Foreign currency translation adjustment

204

-

-

-

Unrealized loss on marketable securities

-217

-

-

-

Other comprehensive income/(loss)

-

15

-

-4

Total comprehensive loss

-13,152

-9,956

-9,188

-10,288

Net loss per share, basic and diluted

-0.56

-12.41

-13.28

-15.90

Weighted average number of shares used in computing net loss per share, basic and diluted

23,266

803

691

646